Latest news with #NGNE
Business Insider
2 days ago
- Business
- Business Insider
Analysts Are Bullish on Top Healthcare Stocks: Neurogene (NGNE), Cogent Biosciences (COGT)
There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Neurogene (NGNE – Research Report) and Cogent Biosciences (COGT – Research Report) with bullish sentiments. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week. Neurogene (NGNE) Stifel Nicolaus analyst Paul Matteis maintained a Buy rating on Neurogene on July 7 and set a price target of $46.00. The company's shares closed last Friday at $21.43, close to its 52-week low of $13.47. According to Matteis is a 3-star analyst with an average return of 2.8% and a 43.2% success rate. Matteis covers the Healthcare sector, focusing on stocks such as Sionna Therapeutics, Inc., KalVista Pharmaceuticals, and BioMarin Pharmaceutical. Currently, the analyst consensus on Neurogene is a Strong Buy with an average price target of $38.20, implying a 76.5% upside from current levels. In a report issued on June 30, BMO Capital also maintained a Buy rating on the stock with a $26.00 price target. Cogent Biosciences (COGT) In a report released today, Sam Slutsky from LifeSci Capital maintained a Buy rating on Cogent Biosciences, with a price target of $20.00. The company's shares closed last Friday at $10.98. According to Slutsky has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -2.6% and a 38.8% success rate. Slutsky covers the Healthcare sector, focusing on stocks such as DBV Technologies SA – American, Abivax SA Sponsored ADR, and Olema Pharmaceuticals. Cogent Biosciences has an analyst consensus of Strong Buy, with a price target consensus of $18.64, a 74.7% upside from current levels. In a report issued on June 30, Citi also maintained a Buy rating on the stock with a $15.00 price target.
Yahoo
18-06-2025
- Business
- Yahoo
Craig-Hallum bullish on Neurogene, initiates with a Buy
As previously reported, Craig-Hallum analyst Albert Lowe initiated coverage of Neurogene (NGNE) with a Buy rating and $50 price target. The firm notes the company is developing NGN-401, an AAV gene therapy for Rett syndrome, a rare and devastating neurodevelopmental disease that impacts girls beginning in infancy and is characterized by developmental regression and symptoms that require lifelong care. Craig-Hallum believes Neurogene is undervalued and that NGN-401 has an elegant design that gives it the upper hand over Taysha's (TSHA) competing program TSHA-102. Looking ahead, the firm thinks NGN-401 is well-positioned to show efficacy advantages over TSHA-102 in the second half of 2025 clinical data update and be the leading gene therapy for Rett. This represents a significant commercial opportunity with pricing of over $2M in a U.S. population of about 6k patients, and Albert models WW NGN-401 sales reaching $1B in 2033, including U.S. sales of about $700M. Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See today's best-performing stocks on TipRanks >> Read More on NGNE: Disclaimer & DisclosureReport an Issue Neurogene initiated with a Buy at Craig-Hallum Neurogene Approves Amendments at Annual Stockholders Meeting Neurogene price target raised to $26 from $22 at BMO Capital Neurogene Highlights Gene Therapy Advancements in New Update Neurogene Reports Q1 2025 Financial Progress and Updates Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
